The expression of tissue factor antigen and activity on the surface of leukemic cells

Tanaka, Masao; Yamanishi, Hiroaki

doi:10.1016/0145-2126(93)90054-o

Cited by 36 publications

(42 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tanaka et al (35) confirmed that the development of disseminated intravascular coagulation in patients with AL prior to chemotherapy is associated with the presence of tissue factor (TF) on the surface of the leukemic cells. TF is a major procoagulant that initiates blood coagulation in vivo and is the membrane protein receptor for factor VII.…”

Section: Discussionmentioning

confidence: 72%

“…Activation of coagulation and secondary activation of fibrinolysis are likely to occur continuously and simultaneously throughout circulation (20,24,34). The activation of coagulation is most likely associated with the leukemic cells circulating in the blood, which may contain procoagulants, and the content of these substances depends on the leukemia subtype (35,36). These substances may be released into the blood from disintegrating cells during relapse.…”

Section: Discussionmentioning

confidence: 99%

“…Clinical parameters of patients with various stages of AL subtypes. cells (35). Coagulation disorders may also occur due to leukemia-associated complications, including infection or organic impairment (45).…”

Section: Discussionmentioning

confidence: 99%

“…TF is a major procoagulant that initiates blood coagulation in vivo and is the membrane protein receptor for factor VII. The resulting factor VIIa activates factors IX and X, leading to thrombin generation and fibrin formation (35,37,38). The TF gene is expressed in cells from patients with AL.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia

Wang

Yang

2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Despite the outstanding advances made over the past decade regarding our knowledge of acute leukemia (AL), relapsed AL remains to be associated with a dismal prognosis. A better understanding of AL relapse and monitoring of the D-dimer and lactate dehydrogenase (LDH) plasma levels following chemotherapy may aid clinicians in determining whether relapse may occur in the subsequent phases of the disease. The present study evaluated D-dimer and LDH levels in 204 patients with relapsed AL. Data were collected at the initial onset of AL, at complete remission (CR) and in patients with relapsed AL. D-dimer plasma levels were significantly increased in patients with initial AL and in patients with relapsed AL (P=0.005 and P=0.007, respectively) but not in those with CR. LDH levels were significantly increased in AL patients at the initial onset of disease and at relapse compared with patients achieving CR, irrespective of cell type. Plasma prothrombin time, activated partial thromboplastin time and fibrinogen levels were not significantly different across patients (with the exception of acute promyelocytic leukemia patients) at the initial onset, relapsed AL or CR. Routine hematological parameters (white blood cell count, hemoglobin, platelet count) were significantly different at the initial onset of AL (P=0.002, P<0.001 and P=0.001, respectively) and during relapsed AL (P=0.009, P=0.003 and P<0.001, respectively) compared with patients achieving CR, suggesting an association between D-dimer, LDH and relapsed AL. These results also indicate that determination of D-dimer and LDH levels may be useful for predicting the probability of relapse during chemotherapy, but should also be combined with routine hematological parameters.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia

Wang

Yang

2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…If untreated, death usually occurs within 6 months in most cases. It was reported that TF is expressed on the human leukemic HL-60 (Freeburn et al, 1995;Kubota et al, 1991;Rickles et al, 1995;Tanaka et al, 1989), Molt-4 (Tanaka, 1989), THP-1 (Tanaka, 1989) cell lines , and on leukemic cells from patients with AML (Andoh et al, 1987;Bauer et al, 1989;Nakasaki et al, 2000b;Tanaka et al, 1989;Tanaka and Kishi, 1990;Tanaka and Yamanishi, 1993) and ALL (Kubota et al, 1991;Nakasaki et al, 2000a). TF is not expressed on the normal peripheral mononuclear cells unless stimulated by endotoxin or other cytokines (Rickles et al, 1995), nor on myeloid precursor cells (Bauer et al, 1989).…”

Section: Tf In Leukemiamentioning

confidence: 99%

Factor VII-Targeted Photodynamic Therapy for Breast Cancer and Its Therapeutic Potential for Other Solid Cancers and Leukemia

Hu¹

2011

Breast Cancer - Current and Alternative Therapeutic Modalities

View full text Add to dashboard Cite

Recurrent venous thrombosis as the presenting manifestation of acute lymphocytic leukemia: Leukemic cell procoagulant activity is not responsible for the hypercoagulable state

Bilgrami

Greenberg

Weinstein

et al. 1995

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

The association of cancer with clinical abnormalities of blood coagulation, including superficial thrombophlebitis, deep vein thrombosis (DVT), and disseminated intravascular coagulation (DIC) is well-known, particularly in patients with solid tumors and acute promyelocytic leukemia (APL). Less commonly appreciated is the potential for the development of venous thromboembolic disease (TED) in patients with acute lymphocytic leukemia (ALL). Multiple mechanisms have been implicated for the activation of coagulation in these patients, with an emphasis on the contribution made by the procoagulant properties of the tumor cells themselves. We present two cases of patients with pre-B cell ALL, both of whom developed recurrent TED as the presenting manifestation of their leukemia and/or heralding relapse. The blast cells from one of the patients were studied for the presence of procoagulant activity (PCA) and by Northern blot analysis for tissue factor (TF) messenger RNA (mRNA). Neither PCA nor TF mRNA could be identified in highly purified populations of the lymphoblast cells. We conclude that recurrent TED can be a manifestation of ALL and that mechanisms other than the release of tumor cell procoagulants should be sought to explain the pathogenesis of thrombosis in some patients.

show abstract

The expression of tissue factor antigen and activity on the surface of leukemic cells

Cited by 36 publications

References 28 publications

Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia

Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia

Factor VII-Targeted Photodynamic Therapy for Breast Cancer and Its Therapeutic Potential for Other Solid Cancers and Leukemia

Recurrent venous thrombosis as the presenting manifestation of acute lymphocytic leukemia: Leukemic cell procoagulant activity is not responsible for the hypercoagulable state

Contact Info

Product

Resources

About